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Introduction
Lipids are hydrophobic (nonpolar), organic mole-
cules insoluble in water, but soluble in organic solvents.1
Because of their insolubility body lipids are generally found
either in compartments, as in the case of membrane-associ-
ated lipids and droplets of triglycerols in adipocytes or
transported throughout the body in association with protein
as lipoprotein particles.2 These particles include chylomi-
crons, very low density lipoproteins (LDL) and high-densi-
ty lipoproteins (HDL) and act as a vehicle for transporting
lipids in aqueous milieu of the circulatory system.1 
Lipid profile is frequently asked by the physicians,
and includes total cholesterol (TC), high-density lipoprotein
(LDL), low-density lipoprotein (LDL) and triglycerides
(TG). The primary purpose of lipid profile testing is for
coronary heart disease risk assessment and management of
atherosclerotic disease.1
A strong inverse relationship exists between High
density lipoprotein Cholesterol (HDL-C) concentration with
coronary heart disease (CHD) risk.3,4 The Framingham
heart study indicates that modifying cholesterol intake and
other risk factors actually reduces the incidence of cardio-
vascular diseases; these reports stress the need of knowing
the accurate levels of cholesterol.5
HDL-C is considered as the single major factor for
atherosclerosis and CHD risk assessment.6 HDL-C estima-
tions show a significantly decreased level in obese cases as
compared to the non-obese controls.7
Hypertriglyceridemia with low levels of HDL are
common abnormalities in diabetics.7 Triglyceride concentra-
tions may reflect the accumulation of atherogenic lipopro-
tein in plasma,8 particularly when they cluster with
increased LDL-C9 and a decreased HDL-C.10-12 LDL-C is
also used to guide the selection of treatment of CHD.13  
According to National Cholesterol Education
Program (NCEP) guidelines, more than 41% of American
adults were estimated to have abnormally high screening
values for cholesterol and to require further evaluation.14,15
TC/HDL ratio has been suggested to be the most important
predictor of premature development of CHD and it should
be included in any coronary risk screening profile. TC/HDL
ratio of more than 4.5 generally requires intervention.6,16,17
These recommendations place increased demands on
total cholesterol, serum triglyceride and HDL-C measure-
ments to be as accurate and reproducible as possible. In eld-
erly patients, one of the Italian study suggests that homocys-
tine LP (a) and TC/HDL cholesterol should also be includ-
ed for scoring the risk of CVD.13 Different substances may
interfere in the analysis of analytes (hemolytic, bilirubin,
and lipemia).1 Lipemia interferes in the TC and HDL-C
analysis and gives high false positive results.18 Previously it
was our departmental policy to advise these patients to go
for lipoprotein electrophoresis, which though accurate was
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Abstract
Objective: It is an everyday routine in laboratories to encounter interference in the analysis of lipids. These like-
ly interferences (hemolysis, icterus and lipemia) are countered by asking physicians and patients to send fresh
and properly collected samples. At the Aga Khan University (AKU) Laboratory, we receive 2-3 lipemic/turbid sam-
ples per day. Previously it was our departmental policy to advise these patients to go for lipoprotein electrophore-
sis, which though accurate was time consuming and not cost effective. We therefore studied ultra
centrifugation/airfuge as an alternate method to clear lipid interference and provide accurate, reliable and cost
effective results.
Methods: Daily 2-3 grossly turbid samples are identified on the lipid bench, 48 samples were received in 4
months (February to May 2004). These samples were analyzed for total cholesterol (TC) and High Density
Lipoprotein -Cholesterol (HDL-C) before and after ultra centrifugation/airfuge.
Results: There was a positive correlation between the lipemia and the false high TC and HDL-C. The mean TC
and HDL-C before ultra centrifugation were 263.06 mg/dl and 39.42 mg/dl respectively and after centrifugation
these became 191.77 mg/ dl and 33.06 mg/dl. P value showed a significant difference in both results.
Conclusion: This study suggests that the removal of turbidity by ultra centrifugation/airfuge is cost effective, less
time consuming and provides accurate reliable results of TC and HDL-C in patients with lipemia interference
JPMA 55:239;2005).
policy to advise these patients to go for lipoprotein
electrophoresis, which though accurate was time consuming
and not cost effective. We therefore studied ultra centrifuga-
tion/airfuge as an alternate method to clear lipid interference
and provide accurate, reliable and cost effective results,
more useful for the physicians' diagnosis and treatment of
high-risk patients. 
Material and Methods
This descriptive study was carried out in section of
Chemical Pathology at Aga Khan University Hospital. The
study included 48 lipemia samples received in the laborato-
ry during a period of 4 months (February - May 2004) for
the analysis of lipid profile.
All the samples for the present study were collected
after 10-12 hours fasting. Venous blood (4-5ml) was collect-
ed in an evacuated B.D. vaccutainer tube with gel and clot
activator. Grossly lipemic samples were identified in the
samples received for the analysis of lipid profile. Routinely
the nonlipemic samples were centrifuged at 3000 rpm for 3
minutes to separate the serum and then analyzed on Hitachi
912, which is a fully automated, discrete, computerized ana-
lyzer which performs potentiometric and photometric
assays. It is composed of two hardware units: a) analytic
and b) control unit.  The characteristic features are a) auto-
mated maintenance functions including pipes, b) 360
test/hour throughput c) automatic calibration performance
followed by quality control.19 Methodology was
Homogenous enzymatic calorimetric, using the reagents,
calibrator and standards of ROCHE
For this study, we separated the serum after centrifu-
gation (3000 rpm for 3-5 minutes) into two tubes, one tube
was retained for direct analysis without ultra centrifugation
and the second tube was sent to processing bench for ultra
centrifugation by using BECKMAN airfuge. The table top
airfuge is a miniature air turbine, which is an exceptionally
safe instrument used to clarify lipemic serum. Its rotors are
designed to meet specific needs and are made of anodized
aluminum held in a place by pressure differential, created
during centrifugation. This fixed angle rotors holds up six
microlitre size tubes. Its maximum speed is 95000 rpm at
207 kPa air pressure. These rotors are ideal for the efficient
sedimentation of small sample volume in short time. We
spun our lipemic serum for 10 minute at a speed of  90,000
rpm.20
Both, total cholesterol and HDL-C on these samples
(neat and airfuged) was analyzed simultaneously on Hitachi
912 using the reagents, calibrator and standards of ROCHE.
In addition our laboratory met the regular national and inter-
national quality control requirement for the analysis of total
cholesterol and HDL-C.  
Statistical Analysis                                           
Mean and standard deviation were used to analyze
the date by SPSS version 11.5. To asses the significant dif-
ference a p-value of 0.01 was taken as significant. The
paired "t" test was applied to calculate significant difference
between with and without ultracentrifugation.
Results
A total of 48 lipemic/turbid samples were received
for analysis of lipid profile in the present study over a peri-
od of four months (February-May 2004). All 48 samples
were analyzed for TC and HDL-C before and after the ultra
centrifugation. Before the ultra centrifugation TC ranged
from 160 mg/dl to 486 mg/dl with a mean of 263.06+87.17
mg/dl and HDL-C ranged from 15 mg/dl to 63 mg/dl with a
mean of 39.42+10.45 mg/dl and the p-value was 0.0022.
While after the ultra centrifugation TC ranged from 92
mg/dl to 467 mg /dl with a mean of 191.77+65.45 mg/dl and
HDL-C ranged from 13 mg/dl to 61 mg/dl with a mean
33.06+9.38 mg/dl (Table).
Discussion
Difficulty in obtaining accurate laboratory measure-
ment of plasma lipid values is not a new concern.21 Many
substances interfere in the analysis of different lipids.
Interference by endogenous and exogenous substances with
assays for clinical analytes is a common problem in 'labora-
tory medicine'. The effect of a substance present in the sam-
ple that alters the correct value of the result is usually
expressed as concentration or activity, for an analyte. There
are four major endogenous compounds that consistently
interfere with laboratory result: hemoglobin, bilirubin,
lipids and para proteins.1
Many a times clinicians call the laboratory with con-
cerns about inconsistent results. One of the common detec-
tion system for these inconsistent results is to compare 
Table. Comparison of TC and HDL-C before and after ultra cen-
trifugation in Lipemic/turbid samples.
TC and HDL-C were significantly different before and after the ultra- cen-
trifugation of lipemic samples.
Before After P value
ultracentrigugation ultracentrifugation
Total Samples 48 48 0.01
HDL-C 39.42+10.45 33.06+9.38 0.0022
Total Cholesterol 263.06+87.17 191.77+65.45 0.000017
Mean  of TC and HDL-C before and after the ultra centrifugation/airfuge
with the P- Value is less than 0.01.
the patient's current result with a previous one i.e.
Delta check.22,23 A second approach is to analyze the sam-
ple with different methods. If the result for the two methods
is different, this suggests that interference is present. If the
results are similar for the two methods either no interference
is present or the interference by the interferent is essentially
the same for the two methods. A third approach is to add
serially high concentration of the putative interferent to
aliquots of the same material.22,23
Routinely we experience that the sample received
for lipid profile analysis are after 10-12 hours fasting, but
some of them appear milky due to lipemia even after this
period. Lipemia is the result of circulating chylomicrons. A
creamy layer floating at the top signals the presence of chy-
lomicrons. While elevated levels of LDL-C do not cause
turbidity, they may cause an orange discoloration of the
sample due to carotenoids bound to LDL particles.1
Chylomicrons are basically large lipoproteins com-
plexes that are made by the gut and serve an important func-
tion in the transport of fats, mainly dietary TG. These are
water soluble and are mixtures of triglycerides (82%) pro-
tein (2% as apoprotein), cholesterol (9% mainly as ester)
and phospholipids (7%). Due to the presence of this large
lipid-protein in more than desirable extent, the plasma
becomes lactescent (turbid).24
Chylomicrons cause interference by turbidity or
light scattering and volume displacement.22 As a patholo-
gist, it is our duty to find out new methods and update our
analysis to provide on time, accurate, and reliable results.
We have to search for easier and less time consuming
methodologies to analyze the TC and HDL-C. One way to
determine the LDL-C is to calculate LDL-C from TC and
HDL-C by the help of Friedewald's equation.  
There are different ways to reduce the interference of
chylomicrons, one way is, to get the sample after 10-12
hours fasting because no chylomicron are generally found
in the blood of healthy person after 10-12 hours fasting.24
Another way is to ask for a lipoprotein electrophoresis for
these lipemic serums because in electrophoresis a promi-
nent band is seen at the origin.1 Previously gel electrophore-
sis was recommended for these patients. Unfortunately the
gel electrophoresis method is time consuming, expensive
and limited requests of lipoprotein electrophoresis are made
by the physicians. 
Recent advances suggest that an easy and cost effec-
tive method is ultra centrifugation. After the ultra centrifu-
gation process the chylomicrons comes in supernatant,
which can be easily separated, from the sample.1
Unfortunately we do not have local data on the role of ultra
centrifugation on lipemia.
Search for reliable biochemical marker for CHD has
been difficult because of complexity of the disease process.
CHD is a multifactorial disease where lipoprotein represent
one of the primary risk factors.3 Accurate decision regard-
ing classification of CHD risk and treatment of above nor-
mal LDL-C concentration depends upon reliable TC meas-
urements.4 Total cholesterol, HDL-C, LDL-C and TG are
recommended in the initial evaluation for classification of
patients into highly desirable, desirable, borderline, high
and very high risk for CHD.13 
Castelli et al have developed a relative risk score for
CHD based on the total cholesterol/high density lipoprotein
(TC/HDL-C) ratio and ratio more than 4.5 generally
required intervention.17,21 A low serum level of HDL-C
appears to be an important risk factor of CHD, particularly
in a population whose serum level of total cholesterol is
high.25 
This study shows that before ultra centrifugation, the
result of HDL and TC was higher as compared to after ultra
centrifugation. This signifies that lipemia interferes with the
analysis of TC and HDL-C.
It is recommended that all milky (lipemia/turbid)
samples should be ultra centrifuged and the report issued
with comments like "After ultra centrifugation due to gross
turbidity/lipemia." This increases the reliability and accura-
cy of the results and avoids lipoprotein electrophoresis.
The study concluded that ultracentrifugation is a
cost-effective, reliable and less time consuming technique
to remove chylomicrosis.
Acknowledgement
The authors thank Dr. Yasmin Bhurgri for editing the
article.
References
1. Gregory LC. Lipids and lipoproteins. In: Christenson RH, Gregory LC,
Johnson LJ. Appleton and Lange's outline review clinical chemistry. New
York:  McGraw Hill, 2001, pp. 27-50.
2. Champe PC. Lipid metabolism. In: Champe PC, Richard AH Lippincott's
illustrated reviews. 2nd edition.  Philadelphia:  Lippincott, 1997, pp.163-205.
3. Subaru AA, Abdul KN. Association of high and low density lipoprotein  sub-
classes to risk of coronary heart disease. Pak Armed Forces Med J 1997;
47:45-7.
4. Schectman G, Sasse EA. Variability of lipid measurement: relevance for the
clinician. Clin Chem 1993;39:1495-1503.
5. Gerald RC, Gary LM,  Jay S, Robert C. Blood lipid measurements (variation
and practical utility). JAMA.1992; 267:1652-9.
6. Hirani S, Dai L, Ishwarlal J. A more valid measurement of low density
lipoprotein cholesterol in diabetic patients. Am J Med 1997;102:48-53.
7. Muhammed SB, Zamir AA, Muhammad S. Lipid profile in obesity  J Ayub
Med Coll  2001;13:31-3.
8. Havel RJ. Role of triglyceride-rich lipoproteins in progression of atheroscle-
rosis. Circulation 1990; 81:694-6.
9. Criqui MH, Golomb BA. Epidemiological aspect of lipid abnormalities. Am J
Med 1998;105:48S-57S.
10. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J
Cardiol 1992;70:3-9.
11. Gotto AM Jr. Triglyceride as a risk factor for coronary artery disease. Am J
Cardiol. 1998; 82:22Q-5Q.
12. Benalian P, Cansier C, Hennache G, Khallour O, Bayer P, Duron F. et al.
Comparison of a new method for the direct and simultaneous assessment of
LDL and HDL-cholesterol with ultracentrifugation and established methods.
Clin Chem 2000;46:493-505.
13. Gerald RC, Gary LM, Mary MK, Parvin PW. The effect of errors in lipid
measurement and assessment. Curr Cardio  Report.2002; 4:501-7.
14. Sehectman G, Patsches M, Sasse EA, Variability in cholesterol measurement:
comparison of calculated and direct LDL cholesterol determinations. Clin
Chem 1996 42:732-7. 
15. Razay G, Heaton KW, Bolton CH. Coronary heart disease risk factor in  rela-
tion to menopause. Q  J Med 1992;85: 889-96.
16. Kannel WB, Castelli WP. Cholesterol in the prediction of atherosclerotic dis-
ease. Framingham study. Ann  Intern  Med 1979;90: 85-91.
17. Castelli WP. Cardiovascular disease in women. Am J Obst Gynaecol.
1988:1046-1060.
18. Glick MR, Ryder KW, Jackson SA. Graphical comparisons of interferences in
clinical chemistry instrumentation. Clin Chem 1986;32:470-5.
19. Roche / Hitachi 912 analyzer reference guide V1.2 2001 3-4. 
20. The Beckman Airfuge. Air-Driven ultracentrifuge Instruction manual, Spinco
business center of Beckman instruments. USA: 1995, pp. 1-4.
21. Superko HR, Bachorik PS, Wood PD. High density lipoprotein cholesterol
measurements: a help or hindrance in practical clinical medicin. JAMA
1986;256: 2714-17.  
22. Martin HK, Ronald JE. Interference with clinical laboratory analysis. Clin
Chem. 1994; 40; 1996-2005.
23. Ladenson JH. Patients as their own control: use of the computer to identify
Laboratory error. Clin Chem 1975;21:1648-53. 
24. Naito HK. Coronary artery disease and disorders of lipid metabolism.In:
Kaplan LA,  Pesce AJ. (eds). Clinical chemistry theory,  analysis and correla-
tion, 3rd ed . New York: Mosby, 1996, pp. 642-81.
25. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P et al. Helsinki
heart study: primary prevention trial with Gemfibrozil in middle aged men
with dyslipidemia. N  Engl J Med 1987; 317:1237-45.
